[2][3] It has five research programs: Cancer Therapeutics; Chronic Disease; Clinical Epidemiology; Regenerative Medicine; and Neurosciences.
[4] Its researchers are studying more than a hundred different diseases, conditions and specialties with an overall focus on translating discoveries and knowledge into better health.
[2] Ronald G. Worton was the research institute's founding CEO and Scientific Director in 2001.
[6][7] During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1.
[9] Results from pre-clinical studies were published in Molecular Therapy in October 2021.